APA (7th ed.) Citation

AK, K., AM, G., S, S., AF, E., AM, A., T, S., . . . H, W. (2026). Therapeutic potential of nicorandil vs nebivolol in attenuating PKC/P38MAPK signaling via PPARγ/KLOTHO/CREB pathway signaling: Molecular docking and experimental validation in rat model of unilateral ureteric obstruction. European journal of pharmacology, 1027, 178962. https://doi.org/10.1016/j.ejphar.2026.178962

Chicago Style (17th ed.) Citation

AK, Khalifa, et al. "Therapeutic Potential of Nicorandil Vs Nebivolol in Attenuating PKC/P38MAPK Signaling via PPARγ/KLOTHO/CREB Pathway Signaling: Molecular Docking and Experimental Validation in Rat Model of Unilateral Ureteric Obstruction." European Journal of Pharmacology 1027 (2026): 178962. https://doi.org/10.1016/j.ejphar.2026.178962.

MLA (9th ed.) Citation

AK, Khalifa, et al. "Therapeutic Potential of Nicorandil Vs Nebivolol in Attenuating PKC/P38MAPK Signaling via PPARγ/KLOTHO/CREB Pathway Signaling: Molecular Docking and Experimental Validation in Rat Model of Unilateral Ureteric Obstruction." European Journal of Pharmacology, vol. 1027, 2026, p. 178962, https://doi.org/10.1016/j.ejphar.2026.178962.